drugset
Drugs / IDegAsp
last change Oct 2023 re-read 2 minutes ago

IDegAsp

Protein / enzyme biologic

Developed for
type 1 diabetes mellitus · type 2 diabetes mellitus
Investigated by
Novo Nordisk A/S

Trials 1 · a red edge is where a trial was stopped

today NCT01174303 · Ph 1
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01174303 Aug → Nov 2010 type 1 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05413369 Comparator Jul 2022 → Oct 2023 type 2 diabetes mellitus Sanofi Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as IDegAsp “IDegAsp (insulin degludec [IDeg]/insulin aspart [IAsp]), a soluble co-formulation of a long-acting basal insulin analogue (IDeg) and a rapid-acting insulin analogue (IAsp) in a...” PMID 26088815 ↗ Jul 2015
1

NCT05413369 ↗
Modality Protein / enzyme biologic “a soluble co-formulation of a long-acting basal insulin analogue (IDeg) and a rapid-acting insulin analogue (IAsp)” PMID 26088815 ↗ Jul 2015
Route Subcutaneous “Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.” NCT01174303 ↗